February 11-14, 2024
Visit Remarque Systems at SCOPE US. This conference brings together stakeholders across the life sciences industry for a week of collaboration, innovation, and strategic decision-making.
Harnessing The Power of Technology to Minimize Subjectivity in Clinical Research
February 14, 2024, 9:15 am EST
There is increasing emphasis on the importance of centralized platforms for accessing and managing clinical trial data, allowing stakeholders to focus on real-time data analysis and interpretation rather than navigating through disparate datasets and systems. For clinical trials involving subjective assessments, this is particularly valuable when variability and bias are more likely to occur. This presentation will focus on the benefits of leveraging technology to quickly identify trends and patterns in clinical studies with subjective endpoints, ultimately expediting issue resolution and driving informed decision-making. The discussion will conclude with case studies demonstrating how real-time expert review of key study data improves overall signal detection, enhancing the likelihood of study success.
Meghan Donahue, Head of Product Management, Remarque Systems
Meghan is passionate about understanding end users’ needs and objectives, identifying where their greatest problem exists, and working collaboratively to ideate ways to solve these problems. With 10 years in the healthcare and life sciences IT industry she applies expert knowledge, industry experience, and relentless energy to act as a liaison between customers and the development team and assist with defining the Remarque Systems Platform strategic vision.
Sofie Reynders, Associate Project Director, Neuroscience, Premier Research
Sofie Reynders is an Associate Project Director, Neuroscience, at Premier Research, and is responsible for the operational delivery of clinical studies in the fields of psychiatry and neurology. With the ever-growing need for real-time review and analysis of data to improve operational insights, Sofie has spent the past two years collaborating with Remarque on the development and utilization of analytics to support this goal, including a blinded data review process.
Martin Strassnig, Consultant, Premier Research
Dr. Martin Strassnig is a board-certified psychiatrist and neurologist whose academic career spans more than 20 years, with 15 years of experience as a clinical investigator. Dr. Strassnig serves as an internal consultant, clinical quality reviewer, and a rater trainer in multiple psychiatric and neurological disorders for Premier Research. He is also an Adjunct Professor of Psychiatry and Behavioral Sciences and Associate Professor of Medical Education at the University of Miami.